Literature DB >> 29112198

Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study.

C-M Cheng1,2, W-H Chang1,3, M-H Chen4,5,6, C-F Tsai1,2,7, T-P Su1,2,7,8, C-T Li1,2,7, S-J Tsai1,2, J-W Hsu1,2, K-L Huang1,2, W-C Lin1,2,7, T-J Chen9, Y-M Bai10,11.   

Abstract

A previous genetic study has suggested that schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) share common disease-associated genes. However, whether individuals with first-degree relatives (FDRs) with schizophrenia have a higher risk of these major psychiatric disorders requires further investigation. This study used Taiwan's National Health Insurance Research Database and identified 151 650 patients with schizophrenia and 227 967 individuals with FDRs with schizophrenia. The relative risks (RRs) of schizophrenia and other major psychiatric disorders were assessed in individuals with FDRs with schizophrenia. The individuals with FDRs with schizophrenia exhibited higher RRs (95% confidence interval) of major psychiatric disorders, namely schizophrenia (4.76, 4.65-4.88), bipolar disorder (3.23, 3.12-3.35), major depressive disorder (2.05, 2.00-2.10), ASD (2.55, 2.35-2.77) and ADHD (1.31, 1.25-1.37) than were found in the total population. Several sensitivity analyses were conducted to confirm these results. A dose-dependent relationship was observed between the risks of major psychiatric disorders and the numbers of FDRs with schizophrenia. The increased risks of major psychiatric disorders were consistent in different family relationships, namely among parents, offspring, siblings and twins. Our study supports the familial dose-dependent co-aggregation of schizophrenia, bipolar disorder, major depressive disorder, ASD and ADHD, and our results may prompt governmental public health departments and psychiatrists to focus on the mental health of individuals with FDRs with schizophrenia.

Entities:  

Mesh:

Year:  2017        PMID: 29112198     DOI: 10.1038/mp.2017.217

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  1 in total

Review 1.  Genetics implicate common mechanisms in autism and schizophrenia: synaptic activity and immunity.

Authors:  Xiaoming Liu; Zhengwei Li; Conghai Fan; Dongli Zhang; Jiao Chen
Journal:  J Med Genet       Date:  2017-03-17       Impact factor: 6.318

  1 in total
  19 in total

1.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

Review 2.  Functional genomics links genetic origins to pathophysiology in neurodegenerative and neuropsychiatric disease.

Authors:  Brie Wamsley; Daniel H Geschwind
Journal:  Curr Opin Genet Dev       Date:  2020-07-04       Impact factor: 5.578

3.  Increased Risk of Atopic Diseases in the Siblings of Patients with Autism Spectrum Disorder: A Nationwide Population-Based Cohort Study.

Authors:  Ying-Xiu Dai; Ying-Hsuan Tai; Yun-Ting Chang; Tzeng-Ji Chen; Mu-Hong Chen
Journal:  J Autism Dev Disord       Date:  2019-11

4.  The Role of Stress in Bipolar Disorder.

Authors:  Eduardo H L Umeoka; Judith M C van Leeuwen; Christiaan H Vinkers; Marian Joëls
Journal:  Curr Top Behav Neurosci       Date:  2021

5.  Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders.

Authors:  Wenjing Zhang; John A Sweeney; Li Yao; Siyi Li; Jiaxin Zeng; Mengyuan Xu; Maxwell J Tallman; Qiyong Gong; Melissa P DelBello; Su Lui; Fabiano G Nery
Journal:  Neuropsychopharmacology       Date:  2020-04-30       Impact factor: 7.853

6.  Diagnostic progression to schizophrenia in 35,255 patients with obsessive-compulsive disorder: a longitudinal follow-up study.

Authors:  Mu-Hong Chen; Shih-Jen Tsai; Chih-Sung Liang; Chih-Ming Cheng; Tung-Ping Su; Tzeng-Ji Chen; Ya-Mei Bai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-24       Impact factor: 5.270

7.  Mapping a shared genetic basis for neurodevelopmental disorders.

Authors:  Matthew Jensen; Santhosh Girirajan
Journal:  Genome Med       Date:  2017-12-14       Impact factor: 11.117

8.  Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review.

Authors:  Manuel Gardea-Resendez; Mehmet Utku Kucuker; Caren J Blacker; Ada M-C Ho; Paul E Croarkin; Mark A Frye; Marin Veldic
Journal:  Front Pharmacol       Date:  2020-04-22       Impact factor: 5.810

9.  At-risk individuals display altered brain activity following stress.

Authors:  J M C van Leeuwen; M Vink; G Fernández; E J Hermans; M Joëls; R S Kahn; C H Vinkers
Journal:  Neuropsychopharmacology       Date:  2018-02-26       Impact factor: 7.853

10.  Disrupted upregulation of salience network connectivity during acute stress in siblings of schizophrenia patients.

Authors:  Judith M C van Leeuwen; Christiaan H Vinkers; Matthijs Vink; René S Kahn; Marian Joëls; Erno J Hermans
Journal:  Psychol Med       Date:  2020-01-16       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.